Evidence map›Paper›PMID 40687244›Full record

ArticleTranslational cancer research2025

Trastuzumab deruxtecan: expanding the role of HER2-targeted therapy in solid tumors.

Hazem Aboaid, Yin Mon Myat, Daniel Thomas Jones, Kyaw Zin Thein

Abstract readEditorialComment
PubMed Full text at PMC Publisher
In one paragraph

Article in Translational cancer research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

4 authors.

Hazem AboaidDepartment of Internal Medicine, Kirk Kerkorian School of Medicine at UNLV, Las Vegas, NV, USA.ORCID https://orcid.org/0000-0002-3085-1549
Yin Mon MyatDepartment of Internal Medicine, One Brooklyn Health-Interfaith Medical Center Campus, Brooklyn, NY, USA.ORCID https://orcid.org/0009-0004-3799-7067
Daniel Thomas JonesTouro University Nevada College of Osteopathic Medicine, Las Vegas, NV, USA.ORCID https://orcid.org/0009-0000-3625-1790
Kyaw Zin TheinDivision of Hematology and Medical Oncology, Comprehensive Cancer Centers of Nevada, Central Valley, Las Vegas, NV, USA.ORCID https://orcid.org/0000-0003-1518-1097

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

cell-free deoxyribonucleic acid (cfDNA)human epidermal growth factor receptor 2-targeted therapy (HER2-targeted therapy)immunohistochemistry (IHC)liquid biopsyTrastuzumab deruxtecan (T-DXd)

Identifiers

PMID40687244
PMCPMC12268644

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.